Anixa Biosciences Inc.

NASDAQ: ANIX · Real-Time Price · USD
2.78
-0.01 (-0.36%)
At close: May 02, 2025, 3:59 PM
2.86
2.88%
After-hours: May 02, 2025, 04:36 PM EDT
-0.36%
Bid 2.7
Market Cap 89.51M
Revenue (ttm) n/a
Net Income (ttm) -12.48M
EPS (ttm) -0.39
PE Ratio (ttm) -7.13
Forward PE -7.9
Analyst Buy
Ask 3
Volume 32,333
Avg. Volume (20D) 78,709
Open 2.81
Previous Close 2.79
Day's Range 2.77 - 2.83
52-Week Range 2.07 - 4.20
Beta 0.52

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the t...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 1983
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ANIX
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for ANIX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 259.71% from the latest price.

Stock Forecasts
3 months ago
+6.05%
Anixa Biosciences shares are trading higher. D Bor... Unlock content with Pro Subscription
3 months ago
+16.6%
Anixa Biosciences shares are trading higher after the company highlighted key business milestones for 2024 and outlined goals for the next year.